πŸ‡ΊπŸ‡Έ FDA
Patent

US 10316073

FCRN antagonists and methods of use

granted A61KA61K38/00A61K38/1709

Quick answer

US patent 10316073 (FCRN antagonists and methods of use) held by The Board of Regents of the University of Texas System expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K38/00, A61K38/1709, A61K45/06, A61P